Table 1. Baseline characteristics of subjects (ITT population).

Demographics	AVA (N=287)	AVA plus raxibacumab (N=286)
Age, years, mean (SD)	36·2 (12·77)	36·1 (12·07)
Sex, n (%)		
Female	150 (52·3)	142 (49·7)
Male	137 (47·7)	144 (50·3)
BMI (kg/m^2), mean (SD)	28·0 (6·21)	28·2 (5·63)
Height (cm), mean (SD)	169·6 (9·60)	170·5 (9·44)
Weight (kg), mean (SD)	80·8 (19·73)	82·1 (18·58)
Ethnicity, n (%)		
Hispanic or Latino	34 (11·8)	31 (10·8)
Not Hispanic or Latino	253 (88·2)	255 (89·2)
Race, n (%)		
White	216 (75·3)	221 (77·3)
Black or African American	61 (21·3)	56 (19·6)
American Indian or Alaska Native	7 (2·4)	1 (0·3)
Asian	2 (0·7)	5 (1·7)
Multiple	1 (0·3)	2 (0·7)
Unknown	0 (0·0)	1 (0·3)

AVA, anthrax vaccine adsorbed; BMI, body mass index; ITT, intent-to-treat; SD, standard deviation.

Table 2. Most frequent treatment-emergent AEs of any cause reported by ≥2 subjects in either treatment group (safety population).

	Subjects, n (%)	
	AVA group (n=286)	**AVA plus raxibacumab group (n=280)**
Any treatment-emergent adverse event	87 (30·4)	80 (28·6)
Injection-site reaction	18 (6·3)	18 (6·4)
Injection-site erythema	11 (3·8)	13 (4·6)
Headache	6 (2·1)	9 (3·2)
Injection-site pain	6 (2·1)	8 (2·9)
Nausea	6 (2·1)	4 (1·4)
Urinary tract infection	6 (2·1)	2 (0·7)
Injection-site swelling	4 (1·4)	3 (1·1)
Upper respiratory tract infection	3 (1·0)	4 (1·4)
Injection-site pruritus	4 (1·4)	1 (0·4)
Pain in extremity	3 (1·0)	3 (1·1)
Fatigue	3 (1·0)	1 (0·4)
Seasonal allergy	3 (1·0)	1 (0·4)
Presyncope	1 (0·3)	3 (1·1)
Viral upper respiratory tract infection	3 (1·0)	0 (0)
Haematoma	0 (0)	3 (1·1)
Vomiting	2 (0·7)	2 (0·7)
Back pain	2 (0·7)	2 (0·7)
Nasal congestion	2 (0·7)	1 (0·4)
Bronchitis	2 (0·7)	1 (0·4)
Injection-site nodule	1 (0·3)	2 (0·7)
Toothache	2 (0·7)	0 (0)
Feeling hot	2 (0·7)	0 (0)
Influenza	2 (0·7)	0 (0)
Pharyngitis streptococcal	2 (0·7)	0 (0)
Tooth infection	2 (0·7)	0 (0)
Abortion spontaneous	2 (0·7)	0 (0)
Sinus congestion	2 (0·7)	0 (0)
Dermatitis contact	2 (0·7)	0 (0)
Paraesthesia	0 (0)	2 (0·7)
Urticaria	0 (0)	2 (0·7)

AE, adverse event.
A subject may have had >1 AE; a subject experiencing multiple occurrences of an AE was counted, at most, once per Preferred Term.